Szydlo, R., Goldman, J.M., Klein, J.P., Gale, R.P., Ash, R.C., Bach, F.H., Bradley, B.A., Casper, J.T., Flomenberg, N., Gajewski, J.L., Gluckman, E., Henslee, D.P., Hows, J.M., Jacobsen, N., Kolb, H.J., Lowenberg, B., Masaoka, T., Rowlings, P.A., Sondel, P.M., van-Bekkum, D.W., van-Rood, J.J., Vowels, M.R., Zhang, M.J., and Horowitz, M.M. Results of allogeneic bone marrow transplants <strong>for</strong> leukemia using donors other than HLAidentical siblings. J.Clin.Oncol., 15: 1767-1777, 1997. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, Moorman AV, Burnett AK; Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. on behalf of the United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup. Br J Haematol. 2009 Mar 20. Minitransplantation Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA, Maris MB, Chauncey TR, Bruno B, Appelbaum FR, Niederwieser DW, Storb RF. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors <strong>for</strong> treatment of acute myeloid leukaemia in first complete remission. Br J Haematol. 2003 Jan;120(2):281-8. Sayer HG, Kroger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K, Schwerdtfeger R, Siegert W, Runde V, Theuser C, Martin H, Schetelig J, Beelen DW, Fauser A, Kienast J, Hoffken K, Ehninger G, Bornhauser M; Cooperative German Transplant Study Group. Reduced intensity conditioning <strong>for</strong> allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003 Jun;31(12):1089-95. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007 Sep 20;25(27):4246-54 Appelbaum FR. What is the impact of hematopoietic cell transplantation (HCT) <strong>for</strong> older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol. 2008 Dec;21(4):667-75. Review. 34
AML hos børn
- Page 1 and 2: Rekommandationer for knoglemarvstra
- Page 3 and 4: Vævstyper og terminologi Ved valg
- Page 5 and 6: 3.valg: 9/10 allel forligelig ubesl
- Page 7 and 8: Petersdorf EW et al: Major-histocom
- Page 9 and 10: Sygdomsspecifikke overvejelser & kr
- Page 11 and 12: Non myeloablativ stamcelletransplan
- Page 13 and 14: Akutte Leukæmier ALL hos voksne AL
- Page 15 and 16: En metaanalyse af 7 studier, hvor a
- Page 17 and 18: Højrisikofaktorer • Fænotype: N
- Page 19 and 20: Kemoterapi Hoelzer, D.F (1993). The
- Page 21 and 22: unrelated transplant in first compl
- Page 23 and 24: ALL hos børn 5% blaster i knoglema
- Page 25 and 26: i det nordamerikanske register, af
- Page 27 and 28: Risikogrupper for AML i 1. CR Lavri
- Page 29 and 30: Autolog KMT Litteraturen på områd
- Page 31 and 32: Gale, R.P., Horowitz, M.M., Weiner,
- Page 33: myelogenous leukemia in first compl
- Page 37 and 38: Eapen M, Rubinstein P, Zhang MJ, Ca
- Page 39 and 40: Point Parameter 0 0.5 1 1.5 2 Blast
- Page 41 and 42: *) Specielt i denne gruppe gælder
- Page 43 and 44: Kantarjian H, O'Brien S, Cortes J,
- Page 45 and 46: Scott BL, Sandmaier BM, Storer B, M
- Page 47 and 48: tiltagende. Patienter med RC og hø
- Page 49 and 50: Donor leukocyte infusion after hema
- Page 51 and 52: � Konstitutionelle symptomer, for
- Page 53 and 54: Responskriterier ved CML Responstyp
- Page 55 and 56: patienter, som statistisk set vil h
- Page 57 and 58: Mauro,M.J. (2006) Defining and mana
- Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
- Page 61 and 62: Der er ingen data, der indicerer at
- Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
- Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
- Page 67 and 68: Der er ikke indikation for autolog
- Page 69 and 70: sequential chemotherapy in poor-ris
- Page 71 and 72: af immunosuppressiv beh. og DLI og
- Page 73 and 74: following high-dose sequential chem
- Page 75 and 76: Marginal Zone Lymfom Senest revider
- Page 77 and 78: Rezvani AR, Storer B, Maris M et al
- Page 79 and 80: eskriver også sammenhæng mellem i
- Page 81 and 82: HCT ved refraktær sygdom (Verdonck
- Page 83 and 84: transplantation for lymphoprolifera
- Page 85 and 86:
Perifere T-Celle Lymfomer Senest re
- Page 87 and 88:
Referencer: Evens AM, Gartenhaus RB
- Page 89 and 90:
Hodgkin Lymfom (HL) Senest revidere
- Page 91 and 92:
Patienter med progressiv sygdom ell
- Page 93 and 94:
Transplant, 12,172-183. Anderlini,P
- Page 95 and 96:
Allogen KMT 1. HLA-identisk søsken
- Page 97 and 98:
Referencer Definition Bacigalupo A,
- Page 99 and 100:
Paroxysmal Nocturn Haemoglobinuri,
- Page 101 and 102:
Autolog transplantation Myelomatose
- Page 103 and 104:
Cavo M, Tosi P, Zagmani E, Cellini
- Page 105 and 106:
Myelofibrose Idiopatisk myelofibros
- Page 107 and 108:
Introduktion Retransplantation af b
- Page 109 and 110:
Den samlede konklusion kunne være,
- Page 111 and 112:
Thalassæmier Senest revideret nove
- Page 113 and 114:
thalassæmifri overlevelse på 66%
- Page 115 and 116:
Kronisk granulomatøs sygdom Senest